Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance

by Marta Araujo-Castro, Eider Pascual-Corrales, Javier Molina-Cerrillo, Teresa Alonso-Gordoa
Published 2021-03-01

The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors

by Ravindra Pramod Deshpande, Sambad Sharma, Kounosuke Watabe
Published 2020-10-01

PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer

by Reem Saleh, Rowaida Z. Taha, Varun Sasidharan Nair, Nehad M. Alajez, Eyad Elkord
Published 2019-07-01

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab

by Erwin H.J. Tonk, Anne S.R. van Lindert, Joost J.C. Verhoeff, Karijn P.M. Suijkerbuijk
Published 2019-08-01

Real‐world efficacy of atezolizumab in non‐small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti‐PD‐1 antibody...

by Naoki Furuya, Makoto Nishino, Kazushige Wakuda, Satoshi Ikeda, Takashi Sato, Ryota Ushio, Shigeru Tanzawa, Masafumi Sata, Kentaro Ito
Published 2021-03-01

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?

by Yaxiong Zhang, Huaqiang Zhou, Li Zhang
Published 2018-12-01

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?

by Paolo A. Ascierto, Grant A. McArthur
Published 2017-08-01

Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review

by Fausto Petrelli, Francesca Consoli, Antonio Ghidini, Gianluca Perego, Andrea Luciani, Paola Mercurio, Alfredo Berruti, Salvatore Grisanti
Published 2021-09-01

Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis

by Angelo Borsarelli Carvalho Brito, Marcos Pedro Guedes Camandaroba, Vladmir Cláudio Cordeiro de Lima
Published 2021-04-01

Experience of using atezolizumab in 1st line therapy of metastatic urothelial cancer

by R. A. Gafanov, A. G. Dzidzaria, V. A. Rebrikova
Published 2019-10-01

Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients

by Song Y. Park, MD, Candice Church, PhD, Nora A. Alexander, BS, Michi M. Shinohara, MD, Kelly G. Paulson, MD, PhD, Karl D. Lewis, MD, Nancy S. Lee, MD, Paul Nghiem, MD, PhD
Published 2021-02-01

Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation

by Rūta Veinalde, Christian Grossardt, Laura Hartmann, Marie-Claude Bourgeois-Daigneault, John C. Bell, Dirk Jäger, Christof von Kalle, Guy Ungerechts, Christine E. Engeland
Published 2017-04-01

Optic Neuritis Possibly Induced by Anti-PD-L1 Antibody Treatment in a Patient with Non-Small Cell Lung Carcinoma

by Sotaro Mori, Takuji Kurimoto, Kaori Ueda, Hiroko Enomoto, Mari Sakamoto, Yukako Keshi, Yuko Yamada, Makoto Nakamura
Published 2018-07-01

Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer

by Kevin Chih-Yang Huang, Shu-Fen Chiang, William Tzu-Liang Chen, Tsung-Wei Chen, Ching-Han Hu, Pei-Chen Yang, Tao-Wei Ke, K. S. Clifford Chao
Published 2020-02-01

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4⁺ T Cells

by Reem Saleh, Salman M Toor, Sarah Khalaf, Eyad Elkord
Published 2019-10-01

Downregulating testosterone levels enhance immunotherapy efficiency

by Luoyang Wang, Guoqiang Jiang, Nan Jing, Xuerun Liu, Huiren Zhuang, Wenfeng Zeng, Wei Liang, Zheng Liu
Published 2021-01-01

Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat

by Lukman O. Afolabi, Lukman O. Afolabi, Jiacheng Bi, Jiacheng Bi, Jiacheng Bi, Xuguang Li, Adeleye O. Adeshakin, Adeleye O. Adeshakin, Funmilayo O. Adeshakin, Funmilayo O. Adeshakin, Haisi Wu, Haisi Wu, Dehong Yan, Dehong Yan, Liang Chen, Liang Chen, Xiaochun Wan, Xiaochun Wan
Published 2021-08-01

SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study

by Lan Mu, Yan Song, Kuaile Zhao, Ying Liu, Qingxia Fan, Xi Wang, Qun Li, Xiaopeng Wang, Jing Huang
Published 2021-05-01

Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma

by Dong-Jun Park, Pil-Soo Sung, Gil-Won Lee, Sungwoo Cho, Sung-Min Kim, Byung-Yoon Kang, Wonhee Hur, Hyun Yang, Soon-Kyu Lee, Sung-Hak Lee, Eun-Sun Jung, Chang-Ho Seo, Joseph Ahn, Ho-Joong Choi, Young-Kyoung You, Jeong-Won Jang, Si-Hyun Bae, Jong-Young Choi, Seung-Kew Yoon
Published 2021-04-01